Ann: BTX 1801 Phase 2a Antimicrobial Study Underway, page-63

Approximately 18.1% reported treatment-emergent adverse events (TEAEs), with the most frequently reported being nasopharyngitis (2.6%) and upper respiratory tract infection (1.3%), as per a 26 March media release.

The two vehicle-controlled, 12-week Phase III Winlevi trials—708-patient Study 25 (NCT02608450) and 732-patient Study 26 (NCT02608476)—have the same coprimary endpoints, with one being a two-point reduction and Investigator’s Global Assessment (IGA) score of 0 (clear) or 1 (almost clear). This endpoint was achieved by 16.1% of Winlevi intention-to-treat (ITT) patients versus 7% vehicle-only patients (p=0.0012) in Study 25. In Study 26, this was 18.7% in Winlevi ITT patients and 4.7% with vehicle-only patients (p<0.0001), as per a July 2018 media release.

Above is the Winlevi data. I don't think its too late as long it can it have similar efficaciousness and less adverse events. Plus CBD is more marketable.